MedTrace Logo

Therapeutic Drug Monitoring for Individualized Clozapine Therapy

NCT03523741 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2019-09-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the factors affecting the occurrence of adverse drug reactions (glucose and lipid metabolism abnormality, changes in liver function index and sleeping tendency) and clinical effects in schizophrenia patients with clozapine treatment

Conditions

Interventions

DRUG

Clozapine

Clozapine is administered orally according to individual prescribed dosing regimens.

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Sang-In Park, Ph. D. · Kyung Hee University Hospital

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-13
Primary Completion
2020-11-30
Completion
2020-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03523741 on ClinicalTrials.gov